# Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma

> **NCT07751744** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Jubilant Therapeutics Inc.** · enrollment: 113 (estimated)

## Conditions studied

- Brain Metastases From Solid Tumors
- Leptomeningeal Disease
- High Grade Glioma (HGG)
- Glioblastoma (GBM)

## Interventions

- **DRUG:** JBI-778

## Key facts

- **NCT ID:** NCT07751744
- **Lead sponsor:** Jubilant Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2028-04-01
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 113 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751744, "Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07751744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*